cytarabine


Also found in: Wikipedia.

cytarabine

 [si-tar´ah-bēn]
an antimetaboliteantineoplastic agent that inhibits DNA polymerase and thus inhibits DNA synthesis during a specific phase of the cell cycle. Administered intravenously to treat acute myelogenous and other types of leukemia. It is also injected intrathecally to treat meningitis associated with leukemia or lymphoma. Called also cytosine arabinoside.

cytarabine

/cy·tar·a·bine/ (ara-C) (si-tar´ah-bēn) an antimetabolite that inhibits DNA synthesis and hence has antineoplastic properties; used in the treatment of acute myelogenous and other types of leukemia and of meningitis associated with leukemia or lymphoma.

cytarabine

(sī-tăr′ə-bēn′)
n.
A cytotoxic compound that inhibits DNA synthesis and is used as a chemotherapeutic agent, usually in combination with other drugs, in the treatment of certain types of leukemia.

cytarabine

[siter′əbēn]
an antineoplastic agent. Also called arabinosylcytosine, ARA-C, cytosine arabinoside.
indications It is prescribed in the treatment of acute and chronic myelocytic leukemia, acute lymphocytic leukemia, and erythroleukemia.
contraindication Known hypersensitivity to this drug prohibits its use.
adverse effects The most serious adverse reactions are bone marrow depression, stomatitis, phlebitis, liver toxicity, fever, and GI disturbances.

cytarabine

AraC, cytosine arabinoside Oncology An antimetabolite analogue of deoxycytidine, used synergistically with antifolates, alkylating agents, and cis-platinum to treat AML Pharmacokinetics Poorly absorbed–±20% absorbed orally, better IV; T1 ⁄ 2, ±2.5 hrs; 90% metabolized to the inactive arabinosyl uracil Side effects N&V, myelosuppression; in high doses, cerebral dysfunction, ataxia

cytarabine

An antimetabolite drug used in the treatment of acute LEUKAEMIA. It is a purine antagonist (see PURINES) and acts by depriving cells of essential metabolic substances. It causes sickness and vomiting, peptic ulcers and depression of bone marrow blood formation. The drug is on the WHO official list. A brand name is Cytosar.

cytarabine

an antimetabolite that inhibits DNA synthesis, and hence has antineoplastic and antiviral properties. Called also cytosine arabinoside, arabinosyl cytosine, ara-C.
References in periodicals archive ?
In this study, treatment with tosedostat, added to conventional therapy with low dose cytarabine demonstrated a higher response rate and longer survival than would be expected by cytarabine alone.
Contract award: delivery of pharmaceutical products cytarabine and doxorubicin.
Inquire before buying of "Global Cytarabine industry" report at http://www.
The results were based on a subgroup analysis, after 12 months of follow-up, in a randomized Phase 2b trial that compared CPX-351 to conventional cytarabine and daunorubicin (7+3 regimen), the current standard of care (ASCO Abstract #6519).
The financial support provided by the LLS Therapy Acceleration Program (TAP) has been important in expediting the completion of the Phase 3, multicenter trial of CPX-351 versus conventional cytarabine plus daunorubicin in older patients with untreated high risk (secondary) AML.
The trial evaluated the addition of either PKC412 (midostaurin) or placebo to daunorubicin/cytarabine in the induction phase, followed by high-dose cytarabine in the consolidation phase; patients who achieved complete remission after consolidation chemotherapy continued treatment with PKC412 (midostaurin) or placebo as a single agent for up to one year[sup.
Contract awarded for 2727-2015 list cytarabine (cytosine arabinoside) injectable solution or powder for parenteral use 100 mg / ml vial or ampule code 671
Cytarabine kullanimi sirasinda bradikardi, perikardit, aritmi veya konjestif kalp yetmezligi gelistiginde ilac ile iliskili olabilecegi mutlaka akla getirilmelidir (3).
According to Mehar news agency, Bortezomib, Cytarabine, Capecitabine, Erlotinib, Vorinostat, and Irinotecan are some of the drugs which were unveiled.
21) In both subtypes, after standard induction therapy with cytarabine and anthracyclines, complete remission can be achieved in approximately 90% of the patient population.
On cycle 2, the patient received intrathecal liposomal cytarabine (Depocyte[R]).